Equity Overview
Price & Market Data
Price: $0.01
Daily Change: +$0.0099 / 99.00%
Daily Range: $0.0₃1 - $0.01
Market Cap: $4,262
Daily Volume: 2,422
Performance Metrics
1 Week: 9,900%
1 Month: 999,900%
3 Months: 9,900%
6 Months: 999,900%
1 Year: 9,900%
YTD: 999,900%
Details
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.